Supplementary Table 1

|  |  |  |
| --- | --- | --- |
| Days postinjection | No ASCs | ASCs |
| Glycerol | Saline | Glycerol | Saline |
| 3 | 46.25 ± 4.33;185 (n=4) | 78.0 ± 20.6;312 (n=4) | 36.3 ± 13.1;101 (n=3) | 71.5 ± 11.79;213 (n=3) |
| 5 | 67.3 ± 24.4;202 (n=3) | 94.3 ± 15.7;283 (n=3) | 88.5 ± 17.2;254 (n=3) | 76.0 ± 3.9;232 (n=3) |
| 8 | 59.3 ± 10.7;178 (n=3) | 79.33 ± 17.42;238 (n=3) | - | - |
| 11 | 44.3 ± 15.8;133 (n=3) | 119.7 ± 19.2;359 (n=3) | 85.0 ± 8.1;255 (n=3) | 79.66 ± 7.17;239 (n=3) |

Number of NMJs per experimental condition. Shown is mean ± SEM per muscle; number of NMJs found in total per condition (n indicates number of analyzed muscles – equals number of mice – per condition).